OB3.F OPTIBIOTIX HLTH PLC LS-02

Healthcare Biotechnology Frankfurt Exchange
0.0520 EUR
Close of Nov 12, 2026
0.0380 0.0930
Market cap
EUR 5.37M
P/E
-
P/B
1.07x
ROE
-61.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is OB3.F undervalued?

Graham number

The Graham number of OPTIBIOTIX HLTH PLC LS-02 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

OPTIBIOTIX HLTH PLC LS-02 fundamental analysis

No fundamental analysis for OPTIBIOTIX HLTH PLC LS-02 yet.

OPTIBIOTIX HLTH PLC LS-02 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About OPTIBIOTIX HLTH PLC LS-02

OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential health benefits. Its first-generation products include Slimbiome, which offers …

Full company profile